ACTEMRA (tocilizumab) recall in Canada: risk of liver injury
In plain language
This recall involves ACTEMRA (tocilizumab) intravenous and subcutaneous solutions sold in Canada. It's being recalled because it may cause serious drug-induced liver injury. Consumers should talk to their healthcare professional if they have concerns about this product.
What to do
- Talk to your healthcare professional if you have concerns about ACTEMRA.
- Discuss any history of liver problems with your doctor.
- Ensure you have blood tests to check liver function before and during treatment.
Get alerts for recalls like this
Get email alerts when new recalls affect products in this category.
Affected products
ACTEMRA (tocilizumab) 20 mg/mL concentrate solution for intravenous infusion (IV)
ACTEMRA (tocilizumab) 162 mg/0.9 mL solution for subcutaneous (SC) injection
Why this matters
Risk of liver injury
Do I have this product?
This recall only applies to specific products. Follow the steps below to check.
- 1
Check the product name
Make sure your product name matches one of the affected products listed above.
If your product matches one or more of the details above, it may be affected by this recall.
If your product does not match these details, it is not affected by this recall.
When in doubt, always check the official notice.
Frequently Asked Questions
Why was this product recalled?
Risk of liver injury
What should consumers do?
Talk to your healthcare professional if you have concerns about ACTEMRA. Discuss any history of liver problems with your doctor. Ensure you have blood tests to check liver function before and during treatment.
Where was the product sold?
This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.
Is there a health risk?
Yes, there may be a health risk. Risk of liver injury
When was this product recalled?
This product was recalled on May 21, 2019.
Is the ACTEMRA brand affected by this recall?
Yes, ACTEMRA products are affected by this recall. This recall involves ACTEMRA (tocilizumab) intravenous and subcutaneous solutions sold in Canada. It's being recalled because it may cause serious drug-induced liver injury. Consumers should talk to their healthcare professional if they have concerns about this product.